AUTHOR=Monda Vincenzo , Lupoli Gelsy A. , Messina Giovanni , Peluso Rosario , Panico Annalisa , Villano Ines , Salerno Monica , Sessa Francesco , Marciello Francesca , Moscatelli Fiorenzo , Valenzano Anna , Molino Leonardo , Lupoli Roberta , Fonderico Francesco , Tortora Anna , Pisano Agata , Ruberto Maria , Gabriella Marsala , Cavaliere Gina , Trinchese Giovanna , Mollica Maria P. , Cipolloni Luigi , Cibelli Giuseppe , Monda Marcellino , Lupoli Giovanni , Messina Antonietta 

TITLE=Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 8 - 2017

YEAR=2017

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00632

DOI=10.3389/fphar.2017.00632

ISSN=1663-9812

ABSTRACT=In this prospective randomized observational study we investigate the effect of adjuvant anastrozole in monotherapy or associated with risedronate on bone physiology and quality of life in postmenopausal, hormone-sensitive early breast cancer women at mild to moderate risk of fragility fractures. 
Methods: 84 women were randomly assigned to receive anastrozole alone (group A) or anastrozole plus oral risedronate (group A+R). At baseline and after 24 months lumbar spine (LS) and femoral neck (FN) BMD were evaluated with dual-energy x-ray absorptiometry and health-related quality of life (HRQoL) was examined using the short-form healthy survey. 
Results: After 24 months, treatment with A+R resulted in a significant increase in T-score for LS (p<0.05) and for FN (p<0.05) whereas women of group A had a statistically significant rate of bone loss both in LS T-score (p<0.05) and in FN (p<0.05). A significant change in T-score BMD was seen for group A+R compared with group A at the LS (p=0.04) and at FN (p=0.04). Finally, group A+R showed an overall significant improvement of health profile (SF-36) in group A (p=0.03).
Conclusion: Postmenopausal breast cancer women with osteopenia during treatment with anastrozole have considerable risk of developing osteoporosis; our findings suggest the usefulness of addition of risedronate in order to prevent aromatase inhibitors-related bone loss, not only in case of high-risk of fractures, but also for women at mild-moderate risk. This determines a significant improvement in bone health and a positive impact on HRQoL.